Surprisingly, we demonstrate that GPR44/DP2 antagonism do not acutely improve insulin secretion in T2DM patients irrespective of the endogenous incretin response, i. e. neither during MMTT nor GGI. The gene discussed is GCG; the disease is type 2 diabetes mellitus.